IMPORTANCE Selective serotonin reuptake inhibitor (SSRI) use among pregnant women is increasing, yet the association between prenatal SSRI exposure and fetal neurodevelopment is poorly understood. Animal studies show that perinatal SSRI exposure alters limbic circuitry and produces anxiety and depressive-like behaviors after adolescence, but literature on prenatal SSRI exposure in humans is limited and mixed.
T he prescription of selective serotonin reuptake inhibitor (SSRI) medications for pregnant women has accelerated over the past 30 years. 1 To some extent, this rise may be attributable to increased awareness of the detrimental effects of untreated prenatal maternal depression (PMD) on women and children, 2 along with early studies failing to document immediate effects of SSRI exposure in offspring (although later rodent studies document postpubertal alterations 3 ). However, little is known about the association between prenatal SSRI exposure and human fetal neurodevelopment.
Serotonin (5-hydroxytryptamine ) plays a vital role in neurodevelopment. In the fetal brain, 5-HT signaling affects cell proliferation, differentiation, neuronal migration, network formation, and synaptogenesis. 4 The 5-HT transporter is widely expressed in the fetal brain in both serotonergic and nonserotonergic neurons, 5 thus providing a developmentally transient target for SSRIs. Atypical serotonergic signaling resulting from prenatal SSRI exposure may alter fetal brain development and subsequent functioning. 6 Animal studies support this idea. Perinatal SSRI exposure in rodent studies is associated with delayed motor development, reduced pain sensitivity, disrupted thalamocortical organization, reduced dorsal raphe neuronal firing, reduced arborization of 5-HT neurons, and altered limbic and cortical circuit functioning. 7, 8 Rodent studies also suggest behavioral consequences of early-life SSRI exposure, including increases in anxiety and depression-like behaviors in adulthood (eg, impaired stress response and grooming, decreased play), 3, 9 and suggest that early perturbations in 5-HT signaling may be associated with neurodevelopment, giving rise to atypical emotion-related behaviors later in life. Literature on prenatal SSRI exposure in humans is limited and mixed. Studies have most consistently reported that prenatal SSRI exposure is associated with a shorter gestational period, lower birth weight, lower Apgar scores, and neonatal abstinence syndrome. 10, 11 Initial studies on longer-term neurodevelopmental consequences have yielded mixed findings; some studies suggest increased internalizing and externalizing behaviors during early childhood, 11, 12 whereas others fail to find such associations. 13 However, consistent with animal studies, 3 a recent national registry study (including >15 000 prenatally SSRI-exposed offspring) found increased rates of depression in early adolescence in youth with prenatal SSRI exposure.
14 Brain imaging provides a window into neurodevelopment, yet human infant and fetal imaging studies of prenatal SSRI exposure are scarce. A recent electroencephalography study found reduced interhemispheric connectivity and lower cross-frequency integration in SSRI-exposed infants, suggesting uncoupling of frontal circuitry. 15 Two infant magnetic resonance imaging (MRI) studies documented changes in gray matter (GM) and white matter (WM) tissue properties in prenatally SSRI-exposed infants (eg, altered fractional anisotropy of the thalamostriatal GM and superior WM fascicule 16 and increased mean diffusivity in several major fasciculi 17 ). Although these studies suggest an association between prenatal SSRI exposure and variation in fetal brain development, they are confounded by sample characteristics (eg, inclusion of very preterm-born infants) or the lack of an untreated PMD comparison group. Based on prior animal studies, we hypothesized that prenatally SSRI-exposed infants would demonstrate altered GM morphology and WM connectivity within the corticolimbic circuit. To test this, we used deformation-based GM morphometry and diffusion probabilistic WM tractography. To more accurately assess the association between prenatal SSRI exposure and the infant brain, we considered the following methodologic advances: 2 comparison groups (healthy controls [HCs] ) and infants exposed to untreated PMD), optimization of image analytics for the infant brain, and enhanced connectivity measures.
Methods

Participants
Data were collected between January 6, 2011, and October 26, 2016. Participants (pregnant women, aged 18-45 years) were recruited through obstetricians, midwives, and psychiatrists. A total of 204 mothers were recruited; 103 infants underwent an MRI scan (eMethods and eTable 1 in the Supplement). Group membership was determined after mothers completed a prenatal mood and medication assessment (between 19 and 39 weeks' gestation). Mothers were assigned to the SSRI group if they self-reported receiving an SSRI at some point in their pregnancy. Sleeping, nonsedated infants underwent an MRI session when they were approximately 3.43 (SD 1.50) weeks of age. The New York State Psychiatric Institute Institutional Review Board approved all procedures and participants provided written informed consent. Participants received financial compensation for their participation.
PMD and Psychiatric Symptoms
Group membership (PMD vs HC) was determined during the prenatal assessment based on the mother's depression scores, assessed via the Center for Epidemiological Studies Depression 19 scale (scores ≥16 were considered indicative of clinically significant depression). Women completed the Schedule for Affective
Key Points
Question Is prenatal exposure to selective serotonin reuptake inhibitors associated with fetal brain development?
Findings In this cohort study including 98 infants, significant gray matter volume expansion was noted in the amygdala and insula, as well as an increase in white matter structural connectivity between these same regions in selective serotonin reuptake inhibitor-exposed infants, compared with infants exposed to untreated prenatal maternal depression and healthy controls.
Meaning In line with prior animal studies, these multimodal brain imaging findings suggest that prenatal selective serotonin reuptake inhibitor exposure has a significant association with fetal brain development.
Disorders and Schizophrenia (SADS), a semistructured diagnostic interview. 18 Owing to time limitations, 20 of the 98 mothers with usable infant MRI data did not complete the SADS (SSRI, 2; PMD, 5; and HC, 13). Postnatal depression was assessed via the CES-D, which was completed by mothers again at the time of their infant's MRI session.
Infant 5-HT Transporter-Linked Polymorphic Region Genotype
To determine infant 5-HT transporter-linked polymorphic region (5-HTTLPR) genotype, saliva samples were collected and genotyped (eMethods in the Supplement). Genotype data were missing for 9 infants, who were excluded from 5-HTTLPR analyses.
MRI Acquisition and Analysis
Structural and diffusion MRI was acquired on a whole-body scanner (MR 750 3T; GE Healthcare) with an 8-channel head coil; eMethods in the Supplement provides details. A T2-weighted structural MRI (single run) and diffusionweighted images (2 runs) were obtained from 98 infants; 80 infants had usable T2-weighted scans and 91 had at least 1 usable diffusion-weighted imaging run (eTable 2 in the Supplement). The T2-weighted images underwent voxel-based morphometry. After preprocessing, diffusion-weighted imaging underwent probabilistic tractography and a recently developed filtering algorithm to curtail false-positive streamline estimates and improve the quantitative interpretability of streamline-based connectivity measures (eMethods in the Supplement provide details).
Statistical Analysis
For both GM morphometry and WM connectivity, linear regression with permutation testing (nonparametric) was used. To examine the effects of SSRI exposure beyond the effects of PMD exposure, primary contrast maps compared the SSRI group vs both PMD and HC infants. Three follow-up contrasts were then conducted, comparing (1) SSRI-exposed vs HC infants, (2) SSRI-vs PMD-exposed infants, and (3) PMDexposed vs HC infants. The following covariates were included in the initial regression model: infant sex, age at scan, birth weight, and mother's postnatal depression score, indexed via the CES-D. Significance of effects was determined using nonparametric permutation tests, which do not assume Gaussian distributions. To control for type I error in voxelbased morphometry, we used conditional Monte Carlo permutation testing (randomize program in Functional MRI of Brain Software Library [FSL] v5.0; 10 000 permutations) with the cluster-extent threshold option (a cluster-forming threshold of z = 3.1; whole-brain correction).
For WM connectivity data, we used both connectionlevel and whole-brain connectome-level analysis. Connectionlevel analysis used the same linear regression model as described above with exhaustive permutation testing in the ImPerm r package (https://cran.r-project.org/web/packages /lmPerm/index.html). Whole-brain connectome-level analysis was done with the Network-Based Statistics Toolbox (NBS, version 1.2). 20 We used 2 methods to control for type I error:
false discovery rate and network-based statistics. These methods are complementary because false discovery rate tests the null hypothesis at the individual connection level, whereas network-based statistics tests at the network level using familywise error. False discovery rate is more sensitive to focal effects, while network-based statistics is more sensitive to distributed network effects; 10 000 permutations were used to determine significance. 
Results
Demographics
SSRI Exposure and GM Volume
Compared with infants not exposed to SSRIs (ie, PMD and HC), SSRI-exposed infants showed a significant GM volume expansion in the right amygdala and insula with medium to large effect sizes (SSRI vs PMD and HC: right amygdala, Cohen d =0.65; 95% CI, 0.06-1.23; right insula, Cohen d = 0.86; 95% CI, 0.26-1.14) as well as in the right superior frontal gyrus and the left occipital gyrus at a whole-brain corrected P value <.05 (randomization permutation; adjusted for standard covariates) ( Figure 1 and Table 2 ). An unadjusted model also showed a significant increase in volume in the right amygdala and right insula at whole-brain corrected P < .05. Compared with PMD infants alone, SSRI-exposed infants showed a significant increase in volume in the right amygdala, right insula, right superior frontal gyrus, and right precuneus at whole-brain corrected P < .05 ( Figure 1 and Table 2 ). Furthermore, compared with HC infants alone, SSRIexposed infants showed a significant increase in volume in the right amygdala, right insula, and right caudate. No regions showed a decrease in GM intensity in the SSRI-exposed group at whole-brain corrected P < .05. There were no significant differences in GM volumes between the PMD and HC groups.
SSRI Exposure and WM Connectivity
Linear regression of the structural connectome (connectivity was defined as streamline counts) revealed a significant increase in connectivity in the SSRI group relative to all infants not exposed to SSRIs (SSRI vs PMD and HC) in the following 4 connections: right amygdala-right insula, left anterior cingulate cortex-left thalamus, right precentral gyrus-right cuneus, and left insula-right precuneus at P < .05 (permutation testing; null hypothesis testing at the individual connection level using false discovery rate). An unadjusted model similarly showed a significant increase in connectivity between the right amygdala and right insula and between the left insula and right precuneus at P < .05. However, at the network level (network-based statistics), the structural connectome showed no significant group differences, suggesting similar topology of the structural connectomes across the 3 groups (Figure 2A) . Fractional anisotropy and mean diffusivity of the structural connectomes showed no significant effects of group at P < .05.
Given the significant increase in GM volumes in the right amygdala and right insula in the SSRI group ( Figure 2B and C), we performed a separate analysis focusing on WM connectivity between the 2 regions to better estimate the effect size. With a large effect size, linear regression showed an increase in structural connectivity in the SSRI-exposed group relative to all non-SSRI-exposed infants (SSRI vs PMD and HC: t = 4.82; P < .001; Cohen d = 0.99; 95% CI, 0.40-1.57; adjusted for the aforementioned covariates). Also with large effect sizes, the SSRI group showed an increase compared separately with either HC (SSRI vs HC: t = 4.68; P < .001; Cohen d = 0.97; 95% CI, 0.36-1.57) or PMD (SSRI vs PMD: t = 3.82; P < .001; Cohen d = 1.16; 95% CI, 0.41-1.89).
We confirmed these results in an additional tractography analysis with a larger total streamline count (ie, 100 million for initial tractography and 5 million for the streamline filtering analysis).
Potential Confounders
Effects of SSRIs on GM volume expansion and increased WM connectivity remained significant after adjusting for maternal age, maternal race/ethnicity, total household income, maternal education, maternal comorbid psychiatric disorders, and infant 5-HTTLPR genotype (eTable 3 and eResults in the Supplement).
Prediction of Brain Changes Associated With Prenatal SSRI Exposure
We assessed the capability of the selected GM and WM measures (amygdala volume, insula volume, and amygdalainsula tract estimate) to predict prenatal SSRI exposure ( Figure 3) . A logistic regression model with both GM and WM (GM and WM model) showed the greatest area under the curve (AUC) of 0.83 (95% CI, 0.63-0.93; leave-1-out crossvalidation), significantly greater than models with either WM (P = .008, Wilcoxon rank sum test; AUC, 0.74; 95% CI, a Exposure to low-level (n = 4), midlevel (n = 7), and high-level (n = 5) SSRI dosage (eMethods in the Supplement) in the first (n = 1), second (n = 2), and third (n = 13) trimesters.
b With diagnosis based on SADS score 18 : major depressive disorder (n = 3) and depressive disorder not otherwise specified (n = 3).
c With diagnosis based on SADS score: major depressive disorder (n = 4) and depressive disorder not otherwise specified (n = 12).
d With diagnosis based on SADS score: bulimia (n = 1), panic disorder (n = 2), generalized anxiety disorder (n = 1), and obsessive-compulsive disorder (n = 1).
e With diagnosis based on SADS score: posttraumatic stress disorder (n = 1), panic disorder (n = 2), agoraphobia (n = 1), obsessive-compulsive disorder (n = 1), and simple phobia (n = 1).
f With diagnosis based on SADS score: posttraumatic stress disorder (n = 1) and simple phobia (n = 4).
0.51-0.87) or GM (P = .003; AUC, 0.67; 95% CI, 0.45-0.84) alone.
The GM and WM model with randomly permuted group labels showed an AUC of 0.41 (1000 iterations).
Discussion
To our knowledge, this is the first study to report increased volumes of the amygdala and insular cortex, as well as increased WM connection strength between these 2 regions, in prenatally SSRI-exposed infants. Our findings suggest a potential association between prenatal SSRI exposure, likely via aberrant serotonin signaling, and the development of the amygdalainsula circuit in the fetal brain. Expression patterns of the 5-HT transporter in the developing brain may underlie the association of prenatal SSRI exposure with altered brain morphology. Exclusively during the prenatal period, 5-HT transporter is expressed in Regression analyses were conducted on gray matter (GM) volume maps, estimated from T2-weighted magnetic resonance imaging and through voxel-based morphometry, using a whole-brain corrected P <.05 (randomization permutation; cluster-extent based correction). The colored areas show an increase in volume in SSRI-exposed infants relative to prenatal maternal depression (PMD) without SSRI exposure (green), healthy controls (HC) (blue), and both groups combined (orange) (SSRI, n = 14; PMD, n = 19; HC, n = 47). Compared with the PMD, HC, and both groups combined, the SSRI group showed significant expansion in volume in the right amygdala and insula compared with the PMD group and combined groups only in the superior frontal gyrus, and compared with combined groups only, the occipital gyrus.
B, Distribution (colored area), quartiles (thick bar), 95% CIs (thin line), and medians (white dots). Open triangles represent individual infant values. The significance of group differences was based on voxelwise analysis (whole-brain corrected using randomization permutation) from the 2 separate clusters in the right amygdala and the anterior insula. au indicates arbitrary unit; c, cortex; g, gyrus.
a P = .03 compared with both the PMD group, P = .02 compared with the HC group, and P = .01 compared with the PMD and HC groups combined, all significant results.
b P = .34 compared with the HC group. Our finding of increased GM volume in the amygdala, anterior insula, and superior frontal gyrus in prenatally SSRIexposed infants is in line with findings from animal studies. In 5-HT transporter knockout mice, studies have shown increased dendritic spine density in the amygdala 24,25 and increased dendritic branching of pyramidal neurons of the infralimbic cortex. 25 Studies also point to effects of pharmacologic blockade of the 5-HT transporter in rodents during the A, White matter structural connectomes (90 regions) estimated using diffusion tractography; across both hemispheres, similar connectome organization was evident in each study group: healthy control (HC) infants, SSRI-exposed infants, and prenatal maternal depression (PMD)-exposed infants without SSRI exposure (permutation tests against 1000 randomized connections; P < .05; SSRI, n = 14; PMD, n = 20; HC, n = 58). B, Upper row shows a map of significant group differences in WM connectivity. Regression analyses were conducted on the connectivity matrix using a whole-brain-corrected P < .05 (randomization permutation; false discovery rate control). Lower row shows a representative WM pathway connecting the right amygdala (red) and the right insula (yellow) color-coded by direction. C, Distributions (colored area), quartiles (thick bar), 95% CIs (thin line), and medians (white dots). Open triangles represent infants. The significance of the group differences was based on a regression model performed on the right amygdala-right amygdala connectivity (exhaustive permutations).
a P < .001 compared with the PMD group, P < .001 compared with the HC group, and P = .001 compared with the PMD and HC groups combined.
b P = .80 compared with the HC group. abnormal amygdala-insula circuitry may be associated with increased vulnerability to anxiety and/or other mood disorders. Amygdala-insula hyperactivity to threats is reported in people who are at risk but not yet meeting criteria for anxiety disorders, suggesting that hyperactivity in this circuit may index increased susceptibility to anxiety disorders. 30 Taken together, the structurally primed circuit in the infant brains could lead to maladaptive fear processing in their later life, such as generalization of conditioned fear or negative attention bias. Prior infant neuroimaging studies report seemingly mixed findings: increased fractional anisotropy of the superior WM pathway 16 and decreased fractional anisotropy and increased mean diffusivity 17 of the WM pathways. However, the first study had no direct comparison of exposure to both SSRI and PMD vs exposure with PMD alone and, in the second study, the association between prematurity and neurodevelopment might confound the results. The effects of SSRIs were present only in the right hemisphere. One study hints at asymmetric distributions of 5-HT receptors. In healthy adults, 5-HT 1A receptor binding estimated by positron emission tomography is higher in the right frontal gyri relative to their left hemispheric counterparts (and higher in the left auditory cortex). 41 It remains to be determined whether the asymmetric expression pattern of 5-HT transporter in adults is also present during the fetal period.
Limitations
Our findings should be interpreted in the context of a few limitations. First, because participants were not randomly assigned to the PMD or SSRI group, there could be unmeasured sample differences. It is possible that women who received an SSRI during pregnancy were more severely depressed than were those with PMD. Because our assessments of depression occurred when women were already receiving the SSRI, this hypothesis requires further investigation. Future human studies could include randomization and placebo control (eg, clinicaltrials.gov Identifier: NCT02185547). Second, the groups in our study differed in sociodemographics (maternal education, income, race/ethnicity, and birth weight). Although we statistically adjusted for these potential confounding variables, future research will be needed to conclusively disentangle SSRI and PMD exposure from these sociodemographic variables. Third, the behavioral and psychological correlates of our volumetric and connectivity findings need to be determined and longitudinal studies will need to examine whether developmental trajectories are affected. Last, the accuracy (eg, sensitivity, but perhaps not reliability 42 ) of the fiber orientation estimates in diffusion probabilistic tractography might be partially limited by a relatively small number of gradient directions (n = 11). However, our selection of scanning parameters was based on multiple factors, not solely on the number of gradient directions, such as spatial resolution (submillimeter in-plane resolution for the small neonatal brains), scan duration, and signal-to-noise ratio that decreases as the number of gradient directions increases.
Conclusions
Use of SSRIs during pregnancy has increased in recent decades, 43 yet their association with fetal neurodevelopment continues to be a topic of considerable debate. Because 
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Receiver operating characteristics analysis curve showing cross-validated diagnostic accuracy of a linear regression model predicting SSRI exposure (leave-1-out cross validation). We tested 3 logistic regression models with different sets of the selected brain measures as predictors: GM+WM (orange), WM (gray), and GM (blue) models (predictors: for GM, right amygdala volume and right insula volume; for WM, amygdala-insula connectivity). Shaded areas are confidence bounds (estimated in 5000 bootstrap samples). Further study is required to better elucidate the effects of gestational SSRI exposure on fetal brain development and later life susceptibility to depressive, cognitive, and motor abnormalities. Such information may eventually allow more informed clinical decisions about how to best treat psychiatric disorders during pregnancy for the benefit of both mother and fetus. 
Association of Brain Development With Prenatal Exposure to SSRIs
eMethods. Detailed Methodology Participants
A total 204 mother-infant dyads participated in the study. MRI scans we collected for 103 infants, five of which were excluded due to apparent imaging artifacts due to excessive head motion. The final study sample thus consisted of 98 mother-infant dyads. A total of 101 infants were not scanned due to: 10 declined MRI session, 10 withdrew, 13 scanner equipment problem, 8 lost to follow up, 14 dropped due to medical complications, 18 scheduling logistics issues, 30 investigators' decision not to scan as a robust number of infants already in N-PMD group relative to expense of scanning. There were no significant differences in demographic variables between the dyads (n=103) with and without (n= 101) infant MRI scans (see eTable 1)
SSRI dosage and duration
The majority (n=13) of mothers in the SSRI group reported taking the medication throughout all three trimesters of their pregnancy. There was, however, variance in the dosages prescribed ( Table 1) . To analyze dosage effects, mothers were binned into low (Fluoxetine≤10mg; Escitalopram≤5mg; Citalopram≤10mg; Sertraline≤50mg; Venlafaxine≤75mg) mid (Fluoxetine11-40mg; Escitalopram 6-15mg; Citalopram 11-30mg; Sertraline 51-150mg; Venlafaxine 76-125mg) and high (Fluoxetine>40mg; Escitalopram >15mg; Citalopram >30mg; Sertraline>150mg; Venlafaxine>125mg) SSRI dosage categories.
5-HTTLPR genotyping
The region encompassing 5-HTTLPR and rs25531 polymorphisms was amplified with primers; FORWARD: 5 TCCTCCGCTTTGGCGCCTCTTCC-3 ; REVERSE: 5 -TGGGGGTTGCAGGGGAGATCCTG-3 via a polymerase chain reaction in multiplex master mix (Qiagen, Calif., USA). Amplicon was resolved on a 2.3% UltraPure™ Agarose (Invitrogen, Carlsbad, CA), and visualized under the UV trans-illuminator. Here, 512 bp and 469 bp bands were called as L and S allele at 5-HTTLPR respectively.
MRI Acquisition
For dMRI, with a minimum possible run duration, both voxel-wise in-plane and angular (i.e., number of noncollinear directions) resolutions were considered. Given the small size of infant brains and under-development of the white matter fascicules, parameters were selected to optimize voxel-wise, in-plane resolution (i.e., sub-millimeter), while maintaining sufficient angular resolution. Considering this, our imaging parameters were: for T2-weighted ). During scanning, and after each run, images were visually inspected for severe motion-related artifacts.
In the case of an infant waking up, the MRI session was paused until he/she fell asleep again; scanning then resumed. A typical MRI session took about two hours. To ensure acquisition of high-quality data with limited head motion, propeller T2 scanning was repeated up to twice and dMRI, up to six times. For each infant, the subsequent MRI analyses were conducted on the single run from each modality with the least amount of head motion.
Volume-by-Volume Quality Assessment in DWI
A trained researcher (VB) examined every volume of DWI in each subject for severe artifact that were persistent to our preprocessing pipeline. 27 infants had at least one bad volume to be excluded. No group differences were found in the number of unusable volumes (Table S1 ).
Structural MRI Analysis: Voxel-Based Morphometry
We found that a typical single VBM pipeline, either in SPM or FSL, failed to produce quality brain extraction and segmentation due to issues specific to infant structural scans (e.g., a thin skull or lack of contrast). Therefore, we systematically tested different analytic methods (e.g., several widely-used methods of brain extraction or tissue segmentation in FSL or SPM) and chose the combination that generated the best quality GM estimation. For this, in each analysis step, trained researchers (CL-C and VB), who were blind to group assignment, visually inspected the quality of every output. The following methods were adopted to ensure accuracy of VBM in terms of segmentation and template estimation ( Figure S1 ). First, T2-weighted images underwent Non-parametric Non-uniform intensity Normalization (N3) correction (RRID:SCR_002484) 1 For brain extraction, N3-corrected images underwent Pediatric Brain Extraction Using Learning-based Meta-algorithm 2 . As we assessed individual output, this algorithm turned out to be superior to other brain extraction tools available in FSL or BrainSuite (http://brainsuite.org/processing/surfaceextraction/bse/). Nevertheless, it failed in several subjects. In those subjects whose brain extraction was poor, we chose intermediate outputs of the meta-algorithm were superior to the final outputs.
Second, for tissue segmentation, we used the segmentation function in SPM 12 using tissue probability maps for the infant brain. 3 This method produced quality tissue segmentation, superior to "FMRIB's Automated Segmentation Tool" or FAST (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FAST). Two images were excluded as we failed to obtain acceptable GM segmentation due to image artifacts.
Third, for template generation and spatial normalization, segmented GM images underwent the Diffeomorphic Anatomical Registration Through Exponentiated Lie algebra (DARTEL) toolbox 4 in SPM12 ( Figure S1 ). This procedure involves estimation of deformations that best align individual GM images by iteratively registering them with their average (template generation). Estimated deformations are then used to spatially normalize (warp) Jacobian-scaled GM images.
Finally, spatially normalized and Jacobian scaled GM images were smoothed using 4mm Gaussian Full-Width-HalfMaximum (FWHM) kernel. We reasoned that, given the smaller infant brain size, a smaller smoothing kernel should be used (e.g., smaller than the 8mm FWHM that is typically used in adult brain analysis). Nevertheless, to avoid any smoothness-specific effects, we confirmed the results with 8mm FWHM.
Diffusion MRI Analysis: Probabilistic Tractography
Before preprocessing, a trained researcher (VB), blind to group assignment, manually checked every volume in each subject for motion-related artifacts that were difficult to detect algorithmically in the infant brain images. These volumes were excluded in the subsequent preprocessing and analysis. In 27 infants, we found at least one unusable volume with subject-specific artifacts; this count did not differ by group (P > 0.9; 2 = 0.728).
DWI was preprocessed using the following pipeline in MRtrix. DWI was first denoised using a novel algorithm based on Random matrix theory that permits data-driven, non-arbitrary threshold for Principal Component Analysis denoising; this method enhances the DWI quality for quantitative and statistical interpretation 5 . Denoised images then underwent eddy current and motion correction, 6 brain extraction from three non-diffusion-weighted images (taking their median), and bias field correction using N4 algorithm (N4ITK), an improved N3 method, in ANTS. 7 We then estimated fiber orientation distributions from each preprocessed data using 2 nd -order integration over fiber orientation distributions (iFOD2). Based on the FODs, probabilistic tractography was performed using constrained spherical devolution (CSD). We used a target streamline count of 10 million across the whole brain. The tractograms were filtered using SIFT with a target streamline count of 3 million. After a primary statistical analysis using these filtered tractograms, we tested whether effects of interest were robust to the tractography and filtering parameters, such as the target streamline count for tractography, SIFT, or a ratio between them. This method permits mapping streamline estimation back to individual's DWI, and updating a reconstruction to improve model fit. This approach renders the streamline counts connecting two brain regions proportional to the total cross-sectional area of the white matter fibers connecting those regions, enhancing streamline counts as a biologically plausible quantity, representing 'structural connectivity'. This was done by repeating tractography and SIFT with a set of extreme parameters (100 million and 5 million target streamlines, respectively) with a filtering factor of 20 (100/5). This generated tractograms of about 100GB per subject (cumulatively more than 9TB for the entire group) with average CPU time of 144 hours (13,000 hours across subjects).
We generated a connectivity matrix from 90 brain regions in each infant from the final filtered tractograms. We used streamline counts as the primary connectivity metric in this study as in a recent human infant imaging study
eResults. Further Results
Potential Confounds of Socioeconomic Status
Given the group differences in SES, of which associations with brain development have been documented 11 , we subsampled our participants to match on SES by excluding non-SSRI participants with lower SES (after sub-sampling, mean SES in SSRI=3·5 vs. mean SES in non-SSRI=3·4). In the SES-matched sub-samples (44 infants for structural MRI and 45 for diffusion MRI), the effects of prenatal exposure to SSRI remained significant (amygdala GM volume: t = 2·739, p = 0·009; insula GM volume: t = 3·214, p = 0·003; amygdala-insula WM connectivity: t = 3·727, p = 0·0008; linear regression and permutation to determine significance).
Dosage Effects
We found non-significant dosage effects on the selected brain measures in the SSRI group (n=13): amygdala GM volume (t = 0.31; p > 0.77; partial eta square = 0.015), insula GM volume (t = 0.96; p > 0.37; partial eta square = 0.133), amygdala-insula structural connectivity (t = -0.5; p > 0.6; partial eta square = 0.039) (permutation testing with linear models; the same covariates were included). Though none reached statistical significance, a positive association between an increase in insula GM volume and a higher dosage showed a medium effect size. Due to the lack of variability in the duration of SSRI exposure, we were unable to examine the effects of timing or duration of exposure.
Tract Based Spatial Statistics
TBSS pipeline generated acceptable spatial normalization except for two scans, which were excluded from the statistical analysis. Randomization permutation showed no significant effects of SSRI on white matter FA tracts at p < 0.05 (corrected at the whole brain level 
